# HEPCAR
## Identification of biomarkers in hepatocarcinoma cell lines using AI

The aim of this project was to study the clinical features of liver cancer sufferers. The findings of this research partnership between AP-HP and Owkin were published in the Hepatology scientific journal: "Predicting survival after hepatocellular carcinoma resection using deep-learning on histological slides"

**Carnot AP-HP**

## Scientific / technological breakthrough

This partnership enabled Carnot AP-HP researchers to use data based on care activity or research to train machine learning, interpretable models. These models can predict patient prognosis and their response to treatment more effectively, thus creating new generations of biomarkers. Owkin then markets the research findings in partnership with Carnot AP-HP to the pharma labs by applying the research in medical trials.





## The competitive advantage for the economic stakeholders

Therapeutic innovation generated by the HEPCAR project was published in the Hepatology scientific journal (Saillard et al., 2020).

By marketing the resulting model to pharmaceutical partners, this therapeutic innovation can be harnessed to identify new targets and gain a better understanding of prognostic biomarkers, thus guiding available therapies by applying the AI model to drug trials. Revenue generated from results capitalization will be shared between AP-HP and Owkin. AP-HP and Owkin have also continued their HCC research — especially into grades B and C — to enhance the treatment available to a greater number of patients and improve scientific knowledge of one of the most lethal forms of cancer.

### Partnership

- **OKWIN,** a start-up seeking to accelerate and improve the discovery of new drugs using artificial intelligence.

**Contact**

Carnot AP-HP - Pauline CREPEL - pauline.crepel@aphp.fr
Owkin - Amandine LAGORCE - amandine.lagorce@owkin.com